Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Background: Pulmonary hypertension (PH) in adults with sickle cell disease (SCD) is associated with early mortality, but no prior studies have evaluated quantitative relationships of mortality to physiological measures of pre- and postcapillary PH. Objectives: To identify risk factors associated with mortality and to estimate the expected survival in a cohort of patients with SCD with PH documented by right heart catheterization. Methods: Nine-year follow-up data (median, 4.7 yr) from the National Institutes of Health SCD PH screening study are reported. A total of 529 adults with SCD were screened by echocardiography between 2001 and 2010 with no exclusion criteria. Hemodynamic data were collected from 84 patients. PH was defined as mean pulmonary artery pressure (PAP) ≥ 25 mm Hg. Survival rates were estimated by the Kaplan-Meier method, and mortality risk factors were analyzed by the Cox proportional hazards regression. Measurements and Main Results: Specific hemodynamic variables were independently related to mortality: mean PAP (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.05–2.45 per 10 mm Hg increase; P = 0.027), diastolic PAP (HR, 1.83; 95% CI, 1.09–3.08 per 10 mm Hg increase; P = 0.022), diastolic PAP − pulmonary capillary wedge pressure (HR, 2.19; 95% CI, 1.23–3.89 per 10 mm Hg increase; P = 0.008), transpulmonary gradient (HR, 1.78; 95% CI, 1.14–2.79 per 10 mm Hg increase; P = 0.011), and pulmonary vascular resistance (HR, 1.44; 95% CI, 1.09–1.89 per Wood unit increase; P = 0.009) as risk factors for mortality. Conclusions: Mortality in adults with SCD and PH is proportional to the physiological severity of precapillary PH, demonstrating its prognostic and clinical relevance despite anemia-induced high cardiac output and less severely elevated pulmonary vascular resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest study with the longest follow-up is the NIH-PH cohort study, which screened 531 patients and followed them for a median of 4.4 years (66, 194).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [66]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the group with pulmonary hypertension, 56.4% had precapillary pulmonary arterial hypertension, with a pulmonary artery occlusion pressure ≤15 mm Hg, and the remainder had pulmonary venous hypertension, with elevated pulmonary artery occlusion pressures >15 mm Hg.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both hemodynamic forms of pulmonary hypertension are independent predictors of death in the adult SCD patient population (66).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of these patients, 84 received right heart catheterizations due to suspected pulmonary hypertension, and 55 (10.4%) were diagnosed with pulmonary hypertension based on a mean pulmonary artery pressure >25 mm Hg.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“The diagnosis of both forms of pulmonary hypertension was associated with a high risk of death”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [66]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191 · cited 1×
“Although PVR is useful, the current precapillary PH classification does not require it as a diagnostic criterion (1, 41).”
BackgroundSelf-citationD'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501 · cited 1×
“In subjects with idiopathic pulmonary arterial hypertension, the NIH registry suggested that three hemodynamic variables (increased PAP, increased CVP, and decreased cardiac index) predicted increased risk of death (26).”
BackgroundThe 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.
Guyatt, G. H., Sullivan, M. J., Thompson, P. J., Fallen, E. L., Pugsley, S. O., Taylor, D. W., & Berman, L. (1985) · Europe PMC (PubMed Central) · Cited by 2,401
Updated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. É. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,383
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330 · cited 1×
“These markers have also been linked to accelerated hemolysis and alterations in nitric oxide bioavailability (48, 51).”
BackgroundPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationVoelkel, N. F., Quaife, R. A., Leinwand, L. A., Barst, R. J., McGoon, M. D., Meldrum, D. R., Dupuis, J., Long, C. S., Rubin, L. J., Smart, F. W., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.632208 · Cited by 1,250
Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy
McLaughlin, V. V., Shillington, A., & Rich, S. (2002) · Circulation · doi:10.1161/01.cir.0000029100.82385.58 · Cited by 1,213
MIYAMOTO, S., NAGAYA, N., SATOH, T., KYOTANI, S., SAKAMAKI, F., FUJITA, M., NAKANISHI, N., & MIYATAKE, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,154 · cited 1×
“Other studies of idiopathic pulmonary arterial hypertension and precapillary PH associated with other disorders have shown clinical variables, such as poor exercise capacity as measured by the 6-minute walk distance (6MWD) test and advanced World Health Organization functional class (WHO FC), and certain biomarkers ar…”
BackgroundDiagnosis and Assessment of Pulmonary Arterial Hypertension
Badesch, D. B., Champion, H. C., Gomez Sanchez, M. A., Hoeper, M. M., Loyd, J. E., Manes, A., McGoon, M., Naeije, R., Olschewski, H., Oudiz, R. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.011 · Cited by 1,138
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00002 · Cited by 1,075
Kircher, B. J., Himelman, R. B., & Schiller, N. B. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90711-9 · Cited by 1,027
Mukerjee, D., St George, D., Coleiro, B., Knight, C., Denton, C. P., Davar, J., Black, C. M., & Coghlan, J. G. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.11.1088 · Cited by 764 · cited 1×
“This prevalence would place SCD as second only to scleroderma (12%) among associated conditions under WHO group I precapillary PH (35, 36) and comparable to portopulmonary hypertension (1–6%) (37) and HIV infection (0.”
BackgroundBerger, M., Haimowitz, A., Van Tosh, A., Berdoff, R. L., & Goldberg, E. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80172-8 · Cited by 742
Kato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661 · cited 1×
“These markers have also been linked to accelerated hemolysis and alterations in nitric oxide bioavailability (48, 51).”
BackgroundSelf-citationKrowka, M. J., Plevak, D. J., Findlay, J. Y., Rosen, C. B., Wiesner, R. H., & Krom, R. A. F. (2000) · Liver Transplantation · doi:10.1053/jlts.2000.6356 · Cited by 611
A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease
Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., Bennani, S., Savale, L., Adnot, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005565 · Cited by 512
Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era
Sitbon, O., Lascoux-Combe, C., Delfraissy, J.-F., Yeni, P. G., Raffi, F., De Zuttere, D., Gressin, V., Clerson, P., Sereni, D., & Simonneau, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200704-541oc · Cited by 457
Causes of death in sickle cell disease: an autopsy study
Manci, E. A., Culberson, D. E., Yang, Y., Gardner, T. M., Powell, R., Haynes, J., Shah, A. K., Mankad, V. N., & Investigators of the Cooperative Study of Sickle Cell Disease (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04594.x · Cited by 350
Haemodynamic evaluation of pulmonary hypertension
Chemla, D., Castelain, V., Hervé, P., Lecarpentier, Y., & Brimioulle, S. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00068002 · Cited by 337 · cited 1×
“15 WHO FC III or IV, n (%) 18 (33) 4 (14) 0.”
Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure.
Powars, D., WEIDMAN, J. A., Odom‐Maryon, T., Niland, J. C., & Johnson, C. M. (1988) · PubMed · Cited by 329
Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival
Castro, O., Hoque, M., & Brown, B. D. (2003) · Blood · doi:10.1182/blood-2002-03-0948 · Cited by 327 · cited 1×
“PH associated with SCD is characterized by relatively modest elevations of mPAP and PVR and a high cardiac output, as seen in this study and others (9, 10).”
ResultSelf-citationDiastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease
Sachdev, V., Machado, R. F., Shizukuda, Y., Rao, Y. N., Sidenko, S., Ernst, I., St. Peter, M., Coles, W. A., Rosing, D. R., Blackwelder, W. C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.038 · Cited by 323
Self-citationPulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298 · cited 1×
“Increasing age is reported with an increased risk of PH in previous studies (2, 4), but mortality was not explained by old age among patients with PH in our study.”
BackgroundSickle Cell Chronic Lung Disease: Prior Morbidity and the Risk of Pulmonary Failure
POWARS, D., WEIDMAN, J. A., ODOM-MARYON, T., NILAND, J. C., & JOHNSON, C. (1988) · Medicine · doi:10.1097/00005792-198801000-00005 · Cited by 282
Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease
Fonseca, G. H. H., Souza, R., Salemi, V. M. C., Jardim, C. V. P., & Gualandro, S. F. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00134410 · Cited by 274
Anthi, A., Machado, R. F., Jison, M. L., Taveira-DaSilva, A. M., Rubin, L. J., Hunter, L., Hunter, C. J., Coles, W., Nichols, J., Avila, N. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200610-1498oc · Cited by 270 · cited 2×
“Our findings are in agreement with previous studies describing the hemodynamic etiology of PH in SCD as heterogeneous (8, 9).”
ResultSelf-citationMathai, S. C., Hummers, L. K., Champion, H. C., Wigley, F. M., Zaiman, A., Hassoun, P. M., & Girgis, R. E. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24267 · Cited by 265 · cited 1×
“The prognostic value of PVR and TPG is shared with scleroderma-associated precapillary PH (44), PH after heart transplantation (45), and portopulmonary hypertension after liver transplantation (46).”
BackgroundDe Castro, L. M., Jonassaint, J. C., Graham, F. L., Ashley‐Koch, A., & Telen, M. J. (2008) · American Journal of Hematology · doi:10.1002/ajh.21058 · Cited by 243
Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension
Mehari, A., Gladwin, M. T., Tian, X., Machado, R. F., & Kato, G. J. (2012) · JAMA · doi:10.1001/jama.2012.358 · Cited by 229 · cited 2×
“Our group and others recently reported a PH prevalence of 6 to 11% in adults with, which is associated with increased hazard of death (7, 8).”
BackgroundSelf-citationMurali, S., Kormos, R. L., Uretsky, B. F., Schechter, D., Reddy, P. S., Denys, B. G., Armitage, J. M., Hardesty, R. L., & Griffith, B. P. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90704-d · Cited by 208 · cited 1×
“The prognostic value of PVR and TPG is shared with scleroderma-associated precapillary PH (44), PH after heart transplantation (45), and portopulmonary hypertension after liver transplantation (46).”
BackgroundPulmonary hypertension in sickle cell hemoglobinopathy: A clinicopathologic study of 20 cases
Haque, A. K., Gokhale, S., Rampy, B. A., Adegboyega, P., Duarte, A., & Saldana, M. J. (2002) · Human Pathology · doi:10.1053/hupa.2002.128059 · Cited by 202
Pulmonary hypertension and nitric oxide depletion in sickle cell disease
Bunn, H. F., Nathan, D. G., Dover, G. J., Hebbel, R. P., Platt, O. S., Rosse, W. F., & Ware, R. E. (2010) · Blood · doi:10.1182/blood-2010-02-268193 · Cited by 202 · cited 1×
“There has been controversy regarding the prevalence of PH in SCD and its contribution to mortality (21, 22, 24).”
BackgroundPulmonary hypertension in sickle cell disease
Sutton, L. L., Castro, O., Cross, D. J., Spencer, J. E., & Lewis, J. F. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90760-9 · Cited by 184
Self-citationTaylor, J. G., Nolan, V. G., Mendelsohn, L., Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002095 · Cited by 184
Self-citationPulmonary Hypertension and Cor Pulmonale during Severe Acute Chest Syndrome in Sickle Cell Disease
Mekontso Dessap, A., Leon, R., Habibi, A., Nzouakou, R., Roudot-Thoraval, F., Adnot, S., Godeau, B., Galacteros, F., Brun-Buisson, C., Brochard, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1606oc · Cited by 170
Hebbel, R. P. (2011) · American Journal of Hematology · doi:10.1002/ajh.21952 · Cited by 169 · cited 1×
“There has been controversy regarding the prevalence of PH in SCD and its contribution to mortality (21, 22, 24).”
BackgroundHemodynamics and Survival of Patients With Portopulmonary Hypertension
Kawut, S. M., Taichman, D. B., Ahya, V. N., Kaplan, S., Archer-Chicko, C. L., Kimmel, S. E., & Palevsky, H. I. (2005) · Liver Transplantation · doi:10.1002/lt.20459 · Cited by 159 · cited 1×
“This prevalence would place SCD as second only to scleroderma (12%) among associated conditions under WHO group I precapillary PH (35, 36) and comparable to portopulmonary hypertension (1–6%) (37) and HIV infection (0.”
BackgroundPulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies
Collins, F. S., & Orringer, E. P. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90763-x · Cited by 142
Gordeuk, V. R., Sachdev, V., Taylor, J. G., Gladwin, M. T., Kato, G., & Castro, O. L. (2008) · American Journal of Hematology · doi:10.1002/ajh.21016 · Cited by 136
Self-citationMachado, R. F., Kyle Mack, A., Martyr, S., Barnett, C., MacArthur, P., Sachdev, V., Ernst, I., Hunter, L. A., Coles, W. A., Nichols, J. P., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06417.x · Cited by 122 · cited 1×
“Additionally, the acute increase in pulmonary artery pressure in the sickle cell vasoocclusive pain crisis (42) and the acute chest syndrome associated with mortality (43) might be more likely to be lethal in these patients with SCD and PH with diminished functional reserve.”
BackgroundSelf-citationPULMONARY HYPERTENSION IN SICKLE CELL DISEASE: Relevance to Children
Kato, G. J., Onyekwere, O. C., & Gladwin, M. T. (2007) · Pediatric Hematology and Oncology · doi:10.1080/08880010601185892 · Cited by 110
Self-citationGraham, J. K., Mosunjac, M., Hanzlick, R. L., & Mosunjac, M. (2007) · American Journal of Forensic Medicine & Pathology · doi:10.1097/01.paf.0000257397.92466.50 · Cited by 107
Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension
Takeda, Y., Takeda, Y., Tomimoto, S., Tani, T., Narita, H., & Kimura, G. (2010) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-10-22 · Cited by 93 · cited 1×
“Another previously identified risk factor, direct bilirubin, reflects an association observed in precapillary PH without SCD (52).”
BackgroundHemodynamic Studies in Sickle Cell Anemia
Leight, L., Snider, T. H., Clifford, G. O., & Hellems, H. K. (1954) · Circulation · doi:10.1161/01.cir.10.5.653 · Cited by 92 · cited 1×
“At their usual baseline, due to their high cardiac output, subjects with SCD with normal mPAP have PVR between 22 and 62 dyn$s$cm(25) (11).”
BackgroundLongitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease
Pashankar, F. D., Carbonella, J., Bazzy‐Asaad, A., & Friedman, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07501.x · Cited by 62 · cited 1×
“Last, supportive care of SCD with hydroxyurea or chronic transfusion has been more aggressively promoted in the last decade, and anecdotal evidence indicates that in some cases this may lead to better control of pulmonary arterial pressures (39, 40).”
BackgroundOlnes, M., Chi, A., Haney, C., May, R., Minniti, C., Taylor, J., & Kato, G. J. (2009) · American Journal of Hematology · doi:10.1002/ajh.21446 · Cited by 45 · cited 1×
“Last, supportive care of SCD with hydroxyurea or chronic transfusion has been more aggressively promoted in the last decade, and anecdotal evidence indicates that in some cases this may lead to better control of pulmonary arterial pressures (39, 40).”
BackgroundSelf-citationPulmonary hypertension in patients with sickle cell disease: not so frequent but so different
Simonneau, G., & Parent, F. (2011) · European Respiratory Journal · doi:10.1183/09031936.00119811 · Cited by 18 · cited 3×
“There has been controversy regarding the prevalence of PH in SCD and its contribution to mortality (21, 22, 24).”
BackgroundLorch, D. G., Spevack, D. M., & Little, J. A. (2011) · Acta Haematologica · doi:10.1159/000323464 · Cited by 15
van Rijswijk, L. (1998) · PubMed · Cited by 12
Nouvelle classification clinique de l’hypertension pulmonaire
Simonneau, G. (2009) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)32423-9 · Cited by 7
Nathan, D. G. (2011) · Blood · doi:10.1182/blood-2011-08-370338 · Cited by 5
Parent, F., Bachir, D., Lionnet, F., Inamo, J., Driss, F., Savale, L., Loko, G., Elmazouzi, A., Letierce, A., Girot, R., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2646 · Cited by 4
Sitbon, O., Jaïs, X., Pavec, J. L., Degano, B., Humbert, M. J. C., & Simonneau, G. (2008) · PubMed · Cited by 4
Hemodynamic Parameters Predict Mortality In Sickle Cell Disease-Related Pulmonary Hypertension
Mehari, A., Tian, X., Alam, S., Xu, D., Seamon, C. A., Gladwin, M. T., Machado, R. F., & Kato, G. J. (2010) · Blood · doi:10.1182/blood.v116.21.2668.2668 · Cited by 3
Self-citation
Research works printed but not linked: 1
- Fonseca, Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease, Eur Respir J
Cited by
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Metadata
- Authors
- Mehari, A., Alam, S., Tian, X., Cuttica, M. J., Barnett, C. F., Miles, G., Xu, D., Seamon, C., Adams-Graves, P., Castro, O. L., Minniti, C. P., Sachdev, V., Taylor, J. G., Kato, G. J., & Machado, R. F.
- Affiliations
- Howard University (US)
- National Heart, Lung, and Blood Institute (US)
- Northwestern University (US)
- University of California, San Francisco (US)
- National Cancer Institute (US)
- University of Tennessee Health Science Center (US)
- University of Illinois Chicago (US)
- Corresponding author
- Kato, Gregory J.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04
- Volume
- 187
- Issue
- 8
- Pages
- 840-847
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC3707372
- OpenAlex
- W2135591520
- Cited by
- 135
- References
- 58
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 14 · 2020: 11 · 2019: 16 · 2018: 11 · 2017: 14 · 2016: 12 · 2015: 6 · 2014: 12 · 2013: 5
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (1ZIAHL006015, 1ZIAHL006012, 1ZIAHL006011)
- National Heart, Lung, and Blood Institute (K23HL098454, ZIAHL006011, ZIAHL006012, ZIAHL006014, ZIAHL006015)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Congenital Heart Disease Studies
- Keywords
- sickle cell disease, pulmonary hypertension, mortality risk factors, hemodynamic predictors, mean pulmonary artery pressure, pulmonary vascular resistance, transpulmonary gradient, pulmonary capillary wedge pressure, survival estimation, adults
- MeSH terms
- Adult, Anemia, Sickle Cell, Clinical Trials as Topic, Female, Follow-Up Studies, Cardiac Catheterization, Humans, Hypertension, Pulmonary, Male, Pulmonary Wedge Pressure, Echocardiography, Doppler, Survival Rate, Logistic Models, Proportional Hazards Models, Risk Assessment, Kaplan-Meier Estimate, Mortality, Premature
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.